ストックスクリーナーアプリを入手
11.04
2.60%
0.28
プレマーケット:
10.95
-0.09
-0.82%
前日終値:
$10.76
開ける：
$10.95
24時間の取引高:
5.97M
Relative Volume:
1.01
時価総額：
$2.40B
収益：
$51.95M
当期純損益:
$-265.94M
株価収益率:
-7.6752
EPS:
-1.4384
ネットキャッシュフロー:
$-216.89M
1週間 パフォーマンス:
+16.21%
1か月 パフォーマンス:
+29.12%
6か月 パフォーマンス:
-13.07%
1年 パフォーマンス:
+69.85%
1日の値動き範囲:
$10.72
$11.23
1週間の範囲:
$8.64
$11.50
52週間の値動き範囲:
$5.80
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Compare OCUL vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
11.04 | 2.34B | 51.95M | -265.94M | -216.89M | -1.4384 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-15 | 開始されました | Chardan Capital Markets | Buy |
| 2025-04-08 | 開始されました | William Blair | Outperform |
| 2025-03-18 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-03-11 | 開始されました | Needham | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-20 | アップグレード | TD Cowen | Hold → Buy |
| 2024-05-31 | 再開されました | Piper Sandler | Overweight |
| 2024-02-09 | 開始されました | BofA Securities | Buy |
| 2023-04-21 | 開始されました | Robert W. Baird | Outperform |
| 2022-08-10 | 再開されました | Berenberg | Buy |
| 2021-08-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-11-13 | 繰り返されました | Raymond James | Strong Buy |
| 2020-08-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-03 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | ダウングレード | Cowen | Outperform → Market Perform |
| 2019-05-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-05-21 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-11-15 | 開始されました | Raymond James | Strong Buy |
| 2018-09-07 | 開始されました | Piper Jaffray | Overweight |
| 2017-10-24 | 開始されました | Guggenheim | Buy |
| 2017-07-26 | 開始されました | H.C. Wainwright | Buy |
| 2017-07-12 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-06-23 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-08-11 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-02-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Ocular Therapeutix Inc (OCUL) 最新ニュース
New Ocular Therapeutix Price Target as Stock Prepares to Blow Through the Old One - TheStreet Pro
Ocular Therapeutix, Inc. (OCUL) Competitors - Meyka
Ocular Therapeutix (OCUL) Gets a Buy from Piper Sandler - The Globe and Mail
Ocular Therapeutix, Inc. (OCUL) Presents at 49th Annual Meeting of the Macula SocietySlideshow - Seeking Alpha
GE Aerospace To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Ocular Therapeutix, Inc. (OCUL) Stock Analysis: 136% Potential Upside Captivates Investor Interest - DirectorsTalk Interviews
Ocular Therapeutix Stock Jumps 22.8% After Conference Update Ahead of Earnings - TIKR.com
Ocular Therapeutix (OCUL): Analyst Raises Price Target Amid Stea - GuruFocus
Short Interest in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Grows By 27.8% - MarketBeat
William Blair Maintains Outperform on Ocular Therapeutix, Inc. (OCUL) March 2026 - Meyka
Ocular Therapeutix Breaks Above 200-Day Moving AverageBullish for OCUL - Nasdaq
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 17.4%Should You Buy? - MarketBeat
Ocular Therapeutix, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Ocular Therapeutix at TD Cowen Conference: Strategic Insights on AXPAXLI By Investing.com - Investing.com Canada
OCUL: Superiority achieved in retina study, paving way for broad label and premium market position - TradingView
Ocular Therapeutix Director Pravin Dugel Sells Shares - TradingView
Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Swings And AXPAXLI Expectations - Yahoo Finance
Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory - Yahoo Finance
Ocular Therapeutix Shares Fall After Inflation Report | 2026 Market UpdateNews and Statistics - IndexBox
Ocular Therapeutix (NASDAQ:OCUL) Cut to Sell at Wall Street Zen - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why - Yahoo Finance
Ocular Therapeutix Highlights Phase 3 AXPAXLI Trial Progress - TipRanks
Ocular Therapeutix to Release SOL-1 Phase 3 AXPAXLI Trial Slides at Macula Society Meeting - TradingView
Ocular Therapeutix chief development officer Kaiser sells $23k in stock - Investing.com India
Sanjay Nayak Sells 1,759 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock - MarketBeat
Peter Kaiser Sells 2,810 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock - MarketBeat
Jeffrey Heier Sells 3,057 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $166,063.68 in Stock - MarketBeat
Ocular Therapeutix, Inc. (OCUL) Investor Outlook: A Biotech With A 205% Potential Upside - DirectorsTalk Interviews
Ocular Therapeutix (NASDAQ:OCUL) Insider Nadia Waheed Sells 3,510 Shares - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Director Richard Md Lindstrom Acquires 60,229 Shares - MarketBeat
Waheed Nadia, Ocular Therapeutix CMO, sells $27k in stock By Investing.com - Investing.com Canada
Waheed Nadia, Ocular Therapeutix CMO, sells $27k in stock - Investing.com South Africa
Ocular Therapeutix Forms Death Cross, Signaling Potential Bearish Trend Ahead - Markets Mojo
Ocular Therapeutix to Participate in March Investor Conferences - Bitget
Ocular Therapeutix™ to Participate in March Investor Conferences - The Manila Times
Ocular Therapeutix Shares Jump After AXPAXLI Hits SOL-1 Phase 3 Endpoint in Wet AMD - MarketBeat
Ocular To Present Detailed Phase 3 SOL-1 Data For AXPAXLI At The 49th Macula Society Annual Meeting - Nasdaq
A Look At Ocular Therapeutix (OCUL) Valuation After Axpaxli Phase 3 SOL-1 Data And Share Price Drop - simplywall.st
Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations - The Manila Times
Ocular Therapeutix (OCUL) Expected to Announce Earnings on Monday - MarketBeat
Reassessing Ocular Therapeutix (OCUL) After Sharp Pullback And Conflicting Valuation Signals - Yahoo Finance
Needham cuts Ocular Therapeutix stock price target on trial results By Investing.com - Investing.com Canada
Tech Rally: Will Ocular Therapeutix Inc. face regulatory challengesJuly 2025 Movers & Weekly Momentum Stock Picks - mfd.ru
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ocular Therapeutix (OCUL) and Sanofi (SNY) - The Globe and Mail
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 9.5%What's Next? - MarketBeat
Ocular Therapeutix Sees Mixed Results with Wet AMD Trial Boost and Stocks Dive - StocksToTrade
Ocular Therapeutix’s Axpaxli Hits Key Milestone in Eye Treatment - timothysykes.com
Needham Maintains Buy Rating on OCUL but Lowers Price Target | O - GuruFocus
Needham cuts Ocular Therapeutix stock price target on trial results - Investing.com
Ocular Therapeutix Inc (OCUL) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):